Tightens orphan drug market exclusivity rules

Bill hr1629-117 ("Tightens orphan drug market exclusivity rules") is before Congress and has not been decided.

Congress file hr1629-117, before Congress. No action in 2008 days as of 2021-05-19.

What it does

You may access competing orphan drugs sooner If a drugmaker receives orphan drug exclusivity but fails to demonstrate it cannot recover development costs within 12 years of U.S. sales, the FDA can approve competing treatments for the same rare disease earlier than the standard seven-year exclusivity period would allow.

The bigger picture

Potential slowdown in rare disease drug development Stricter exclusivity rules may reduce financial incentives for pharmaceutical companies to develop treatments for rare diseases, since shorter or conditional market protection periods lower expected returns on R&D investment.

What to watch

Retroactive application creates uncertainty for existing drugs The bill applies the new 12-year cost-recovery standard to orphan drugs already approved before enactment, potentially triggering re-evaluation and loss of exclusivity for drugs currently on market.

Official summary

Fairness in Orphan Drug Exclusivity Act This bill limits which orphan drugs may be granted a market exclusivity period by the Food and Drug Administration (FDA). (Generally, an orphan drug is one that is not economically viable because of the rarity of the disease that it treats. The sponsor of an FDA-designated orphan drug may be granted various incentives, such as a seven-year period in which the FDA may not grant market approval to a different sponsor for the same drug to treat the same disease.) Under this bill, if a drug is designated as an orphan drug on the basis that there is no reasonable expectation that the sponsor will recover the costs of developing and distributing the drug from U.S. sales, the drug shall be granted the seven-year exclusivity period only if the sponsor demonstrates that there is no reasonable expectation that it will recover such costs specifically within its first 12 years of U.S. sales of the drug. This requirement shall also apply retroactively to an orphan drug that was granted such an exclusivity period before this bill's enactment. When deciding whether an orphan drug meets this requirement, the FDA shall consider the sales of all drugs from the

How they voted

Yes (272)

No (15)

Did not vote / other (4)

Read the official record for hr1629-117

See everything up for a vote · This week in Congress · See what we have filed with the clerk